Having trouble accessing articles? Reset your cache.

Pridopidine: Phase II data

The double-blind, U.S. and Canadian Phase II HART trial in 227 patients showed that 45 mg twice-daily Huntexil missed the primary endpoint of significantly improving voluntary motor function as measured by

Read the full 316 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE